Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05641935 · ClinicalTrials.gov registry record · Phase 2

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

A Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, sponsored by john eisenbrey.

Recruiting
Registry status
Phase 2
Development phase
210
Enrollment target
1
Study location

NCT05641935 is a Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma that is actively recruiting participants, run by john eisenbrey. The registered enrollment target is 210 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05641935, a Phase 2 study of Renal Cell Carcinoma and Recurrent Renal Cell Carcinoma, is actively recruiting participants, sponsored by john eisenbrey.

RECRUITING
Registry status
Phase 2
Development phase
210 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Conditions Studied

Renal Cell Carcinoma Recurrent Renal Cell Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Electronic Health Record Review
  • PROCEDURE Contrast-Enhanced Ultrasound
  • DRUG Sulfur Hexafluoride Lipid Microspheres

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2022-11-03
Est. Completion 2027-08-31
Phase Phase 2

Sponsor

john eisenbrey

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05641935

The ClinicalTrials.gov registry entry for NCT05641935 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (13% lower). The listed sponsor is john eisenbrey, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT05641935 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05641935 about?

NCT05641935 is a clinical study titled "Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation". This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or m...

What is the current status of trial NCT05641935?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2022-11-03. Estimated completion is 2027-08-31.

What conditions does trial NCT05641935 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma.

What interventions are being tested in trial NCT05641935?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Electronic Health Record Review (OTHER), Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG).

Who is sponsoring clinical trial NCT05641935?

This trial is sponsored by john eisenbrey, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05641935 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Recurrent Renal Cell Carcinoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.